Jpmorgan Chase & CO Aeterna Zentaris Inc. Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022
SELL
$0.17 - $0.37 $2,465 - $5,365
-14,500 Reduced 38.88%
22,793 $4,000
Q1 2022

May 11, 2022
SELL
$0.33 - $0.42 $9,669 - $12,306
-29,300 Reduced 44.0%
37,293 $14,000
Q4 2021

Feb 10, 2022
SELL
$0.36 - $0.77 $2,882 - $6,165
-8,007 Reduced 10.73%
66,593 $24,000
Q3 2021

Nov 12, 2021
BUY
$0.59 - $0.88 $44,014 - $65,648
74,600 New
74,600 $56,000

About Aeterna Zentaris Inc.

AEZS Quotes by TradingView
  • Ticker AEZS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 4,855,880
  • Market Cap $19.4M
  • Description
  • Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...
More about AEZS
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email